Sana Biotechnology, Inc. (SANA)


+0.05 (+1.39%)
Symbol SANA
Price $3.66
Beta 0.703
Volume Avg. 0.97M
Market Cap 720.808M
Shares () -
52 Week Range 2.99-8.005
1y Target Est -
DCF Unlevered SANA DCF ->
DCF Levered SANA LDCF ->
ROE -77.15% Strong Sell
ROA -50.42% Strong Sell
Operating Margin -
Debt / Equity 31.87% Neutral
P/E -1.99 Sell
P/B 1.98 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest SANA news

Dr. Steven D. Harr M.D.
NASDAQ Global Select

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.